Description
Vaxcyte Inc. is a clinical-stage vaccine company focused on developing vaccines to protect humankind from the consequences of bacterial diseases. The Company’s pipeline includes pneumococcal conjugate vaccine (PCV), VAX-24, VAX-XP, VAX-A1 and VAX-PG.
The Company’s PCV candidates is in development, targeting global pneumococcal vaccine market. The Company’s lead vaccine candidate, VAX-24, is a 24-valent, broad-spectrum investigational PCV being developed for the prevention of invasive pneumococcal disease (IPD) and pneumonia.
The Company’s PCV candidate, VAX-XP, leverages its scalable and modular platform and builds on the technical proof-of-concept established by VAX-24. VAX-A1 is a novel conjugate vaccine candidate designed to prevent Group A Strep pervasive disease. VAX-PG is a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis and chronic oral inflammatory disease.
